Mechanisms for multiple myeloma osteolytic bone disease; role of hepatocyte growth factor and toll like receptor agonists (forsker)
gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation.
J Endocrinol 2014 Nov;223(2):181-90. Epub 2014 sep 16
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Blood Cancer J 2014;4():e196. Epub 2014 mar 21
The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation.
J Bone Miner Res 2014 Jun;29(6):1492-505.
Anti-c-MET Nanobody(®) - a new potential drug in multiple myeloma treatment.
Eur J Haematol 2013 Aug 17. Epub 2013 aug 17